Clinical trial
Phase II Study of AZD9291 in Patients With Advanced Stage Non-small Cell Lung Cancer Following Prior EGFR TKI Therapy With EGFR and T790M Mutations Detected in Plasma Circulating Tumor DNA (PLASMA)
NCT02811354 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of AZD9291 in Patients With Advanced Stage Non-small Cell Lung Cancer Following Prior EGFR TKI Therapy With EGFR and T790M Mutations Detected in Plasma Circulating Tumor DNA (PLASMA)
- Lead sponsor
- National University Hospital, Singapore
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- February 24, 2017
- Completion date
- February 24, 2020
- Enrollment
- 108 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.